Success Metrics

Clinical Success Rate
82.7%

Based on 67 completed trials

Completion Rate
83%(67/81)
Active Trials
19(16%)
Results Posted
49%(33 trials)
Terminated
14(12%)

Phase Distribution

Ph early_phase_1
2
2%
Ph phase_1
30
26%
Ph phase_2
52
45%
Ph phase_4
5
4%
Ph not_applicable
7
6%
Ph phase_3
16
14%

Phase Distribution

32

Early Stage

52

Mid Stage

21

Late Stage

Phase Distribution112 total trials
Early Phase 1First-in-human
2(1.8%)
Phase 1Safety & dosage
30(26.8%)
Phase 2Efficacy & side effects
52(46.4%)
Phase 3Large-scale testing
16(14.3%)
Phase 4Post-market surveillance
5(4.5%)
N/ANon-phased studies
7(6.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.1%

67 of 88 finished

Non-Completion Rate

23.9%

21 ended early

Currently Active

19

trials recruiting

Total Trials

116

all time

Status Distribution
Active(26)
Completed(67)
Terminated(21)
Other(2)

Detailed Status

Completed67
Terminated14
Recruiting13
Withdrawn7
Not yet recruiting7
Active, not recruiting6

Development Timeline

Analytics

Development Status

Total Trials
116
Active
19
Success Rate
82.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (1.8%)
Phase 130 (26.8%)
Phase 252 (46.4%)
Phase 316 (14.3%)
Phase 45 (4.5%)
N/A7 (6.3%)

Trials by Status

withdrawn76%
not_yet_recruiting76%
terminated1412%
unknown22%
active_not_recruiting65%
completed6758%
recruiting1311%

Recent Activity

Clinical Trials (116)

Showing 20 of 116 trialsScroll for more
NCT05177822Phase 2

Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure

Active Not Recruiting
NCT03511118

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Recruiting
NCT04381936Phase 3

Randomised Evaluation of COVID-19 Therapy

Recruiting
NCT07191444

A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease

Recruiting
NCT02902731Phase 3

Giant Cell Arteritis and Anakinra Trial

Terminated
NCT05267821Phase 2

Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

Recruiting
NCT04205838Phase 2

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

Terminated
NCT05174507Phase 2

Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes

Withdrawn
NCT00339157Phase 2

Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS

Completed
NCT02021422Phase 1

A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy

Completed
NCT07410312Early Phase 1

BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction

Not Yet Recruiting
NCT06381661Phase 2

Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial

Not Yet Recruiting
NCT05611710Phase 2

Anakinra in Dengue With Hyperinflammation ( AnaDen )

Active Not Recruiting
NCT05013450Phase 1

Dupilumab_Metastatic NSCLC

Active Not Recruiting
NCT07281027Phase 3

COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"

Not Yet Recruiting
NCT04150913Phase 2

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Completed
NCT06062966Phase 1

The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART)

Recruiting
NCT04926467Phase 2

Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)

Recruiting
NCT04148430Phase 2

A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy

Active Not Recruiting
NCT04898231Phase 2

MIS-C Comparative Effectiveness Study

Completed

Drug Details

Intervention Type
DRUG
Total Trials
116